This meeting took place in 2015

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

PI 3-Kinase Signaling Pathways in Disease (J2)

Organizer(s) Lori Friedman, David A. Fruman and Phillip T. Hawkins
January 13—18, 2015
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Discounted Abstract Deadline: Sep 24, 2014
Abstract Deadline: Oct 16, 2014
Scholarship Deadline: Sep 24, 2014
Discounted Registration Deadline: Nov 13, 2014

Sponsored by AstraZeneca, Genentech, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc. and Mersana Therapeutics

Summary of Meeting:
The PI3K-Akt-mTOR signaling pathway is one of the primary mechanisms for controlling cell growth, survival and motility in response to intracellular signaling and extracellular cues. Genetic events resulting in inappropriate activation of this pathway are common in many cancers and, as a result, are a focus of both basic cancer research and drug discovery efforts in oncology. The PI3K-Akt-mTOR network also controls diverse aspects of inflammation and adaptive immunity. Although originally modeled as an independent and linear signaling cascade, today it is evident that the PI3K pathway also functions as a central hub for cross-talk in both vertical as well as reciprocal feedback regulation with other important signaling pathways. How metabolic pathways are regulated to meet the unique needs of tumor cells and activated lymphocytes is a fertile area of study, with mounting evidence that metabolic regulation is intimately linked with the signal transduction pathways that control cell growth and proliferation. One of the exciting advances in the field is the development of new inhibitors against this pathway. However, the rationale for inhibiting individual or multiple isoforms of PI3K/Akt/mTOR signaling remains a subject of intense debate. This Keystone Symposia meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI3K- and related pathways in disease, drawing on human pathophysiology and genetics, preclinical models and clinical data on PI3K pathway inhibitors. The joint meeting on “Integrating Metabolism and Tumor Biology” will enhance opportunities for interdisciplinary interactions.

View Meeting Program


Early Career Investigator Travel Award Recipients
made possible by National Institute for General Medical Sciences (NIGMS) Ancillary Training Program Funding

Chastity Nicole Bradford
Tuskegee University, USA

Keystone Symposia Future of Science Fund Scholarship Recipients

Carrie L. Lucas
Yale University, USA

National Institute of General Medical Sciences (NIGMS) Ancillary Training Program Scholarship Recipients

Jennifer L. DeLeon
Stony Brook University, USA

National Cancer Institute (NCI) Scholarship Recipients

Svetlana A. Fayngerts
Adaptimmune LLC, USA

Christl Gaubitz
University of Geneva, Switzerland

Nipun Jayachandran
University of Manitoba, Canada

Miguel Murillo
Institute of Cancer Research, UK

Yan-xia Ye
Peking Union Medical College Hospital, China